CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 220 enrolled
Drug / intervention
Clarithromycin modified release 500 mgdrug
Likely dose
Clarithromycin modified release 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01354938
NCT01354938N/ACompleted
CompareCT.gov

Outcome Study to Evaluate the Role of Klaricid XL (Clarithromycin Modified Release) in the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Its Impact on Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ)

Abbott·observational·Posted May 17, 2011·Updated Feb 6, 2013

In Brief

An observational study evaluating Clarithromycin modified release 500 mg for Bronchitis. Completed, enrolled 220 participants across 28 sites.

Detailed Summary

The objective of this study was to evaluate the role of Klaricid XL (clarithromycin modified release) in the treatment of acute exacerbation of chronic bronchitis (AECB) and its impact on improving the quality of life.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBronchitis
CountriesPakistan
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.1 years ago

Interventions

Clarithromycin modified release 500 mgdrug

Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.